{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=11", "query": { "intervention": "Combination Agent", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 5568, "total_pages": 557, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T11:02:13.152Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07280702", "title": "Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriatic Arthritis (PsA)" ], "interventions": [ { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 128, "start_date": "2026-06-16", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07280702" }, { "nct_id": "NCT04977453", "title": "GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Cervical Cancer", "Urothelial Carcinoma", "Clear Cell Renal Cell Cancer (ccRCC)", "Squamous Cell Non Small Cell Lung Cancer" ], "interventions": [ { "name": "GI-101", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "GI-101A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GI Innovation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2021-08-02", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 3, "location_summary": "New York, New York • Huntersville, North Carolina", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04977453" }, { "nct_id": "NCT01485731", "title": "Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Nelfinavir", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pelvic External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Pharmacokinetic Sampling", "type": "PROCEDURE" }, { "name": "Cervical Biopsy", "type": "PROCEDURE" }, { "name": "Pelvic Examination", "type": "PROCEDURE" }, { "name": "Pap Smear", "type": "PROCEDURE" }, { "name": "Audiogram", "type": "PROCEDURE" }, { "name": "Proctoscopy", "type": "PROCEDURE" }, { "name": "Cytoscopy", "type": "PROCEDURE" }, { "name": "Renal Ultrasound", "type": "PROCEDURE" }, { "name": "CT Scan", "type": "PROCEDURE" }, { "name": "Whole Body PET/CT Scan", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 8, "start_date": "2012-01", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485731" }, { "nct_id": "NCT00001039", "title": "Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mycobacterium Avium-intracellulare Infection", "HIV Infections" ], "interventions": [ { "name": "Ethambutol hydrochloride", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 24, "start_date": null, "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2012-10-31", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 8, "location_summary": "Tucson, Arizona • Baltimore, Maryland • Camden, New Jersey + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Camden", "state": "New Jersey" }, { "city": "Albany", "state": "New York" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001039" }, { "nct_id": "NCT05575999", "title": "Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pain Management" ], "interventions": [ { "name": "Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kansas City Heart Rhythm Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2026-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 3, "location_summary": "Loma Linda, California • Overland Park, Kansas", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05575999" }, { "nct_id": "NCT07849231", "title": "A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloproliferative Neoplasms (MPNs)" ], "interventions": [ { "name": "DMR-001", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Damora Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2026-09", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07849231" }, { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" }, { "nct_id": "NCT02412111", "title": "A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Tezacaftor/Ivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 156, "start_date": "2015-06", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Oakland, California • San Diego, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02412111" }, { "nct_id": "NCT01411137", "title": "Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "IPX066", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Impax Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 43, "start_date": "2011-08", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2019-11-07", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 8, "location_summary": "Birmingham, Alabama • La Jolla, California • Sunnyvale, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Sunnyvale", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Bingham Farms", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01411137" }, { "nct_id": "NCT07491445", "title": "Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Cancer Metastatic", "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Pancreatic Adenocarcinoma Metastatic", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma" ], "interventions": [ { "name": "daraxonrasib", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 900, "start_date": "2026-03-09", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-11-15T11:02:13.152Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07491445" } ] }